FCM
NKTR icon

Farallon Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Farallon Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$288K Buy
+4,000
New +$228K ﹤0.01% 123
2025
Q4 		– Sell
-791,000
Closed -$45M – 163
2025
Q3 		$45M Buy
+791,000
New +$26.2M 0.18% 60
2014
Q2 		– Sell
-12,333
Closed -$2.24M – 107
2014
Q1 		$2.24M Sell
12,333
-28,334
-70% -$5.61M 0.04% 74
2013
Q4 		$6.92M Hold
40,667
– – 0.14% 62
2013
Q3 		$6.38M Buy
+40,667
New +$7.52M 0.13% 62

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Farallon Capital Management's NKTR Position: Q1 2026 in Review

Farallon Capital Management opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 4,000 shares worth $288K. The stake represents ﹤0.01% of the portfolio and ranks #123 among its holdings. This is a return to the name: Farallon Capital Management previously reported a position in NKTR as recently as Q3 2025.

Farallon Capital Management first reported a position in NKTR in Q3 2013 and has held it in 5 quarters since. The position peaked at $45M in Q3 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Farallon Capital Management held 4,000 shares of Nektar Therapeutics worth $288K as of Q1 2026.
  • Nektar Therapeutics was a new Farallon Capital Management position in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Farallon Capital Management's portfolio in Q1 2026, its #123 holding.
  • Farallon Capital Management first reported a position in Nektar Therapeutics in Q3 2013 and has held it in 5 quarters since.
  • Farallon Capital Management's Nektar Therapeutics position peaked at $45M in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.